Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Merck : FDA to Review Merck's Emergency Use Authorization Request For Molnupiravir COVID-19 Drug Nov. 30

10/14/2021 | 02:59pm EST


ę MT Newswires 2021
All news about MERCK & CO., INC.
11:45aEgypt Clears Merck & Co.'s COVID-19 Pill For Emergency Use
MT
11:06aEU Drug Regulator Reportedly Will Decide on Approval of Pfizer's COVID-19 Pill by End o..
MT
09:08aUS FDA Declines Approval For Merck &Co.'s New Cough Drug, Seeks Further Information
MT
08:19aEU Medicines Watchdog to Issue Decision on Pfizer's COVID-19 Pill in January
MT
07:23aFDA Declines to Approve Merck's Investigational Cough Treatment Gefapixant
MT
07:19aMERCK : FDA Rejects Gefapixant Application, Requests More Data
DJ
06:46aMerck Provides U.S. and Japan Regulatory Update for Gefapixant
BU
01/21Strides and its African subsidiary Universal Corporation partner with Medicines Patent
AQ
01/21Eisai - Results From Pivotal Phase 3 Study 309/KEYNOTE-775 Trial of LENVIMA (lenvatinib..
AQ
01/21Merck - RESULTS FROM PIVOTAL PHASE 3 KEYNOTE-775/STUDY 309 TRIAL OF KEYTRUDA (PEMBROLIZ..
AQ
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Financials (USD)
Sales 2021 48 415 M - -
Net income 2021 11 938 M - -
Net Debt 2021 17 130 M - -
P/E ratio 2021 17,1x
Yield 2021 3,27%
Capitalization 202 B 202 B -
EV / Sales 2021 4,53x
EV / Sales 2022 3,79x
Nbr of Employees 73 500
Free-Float -
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 79,98 $
Average target price 92,27 $
Spread / Average Target 15,4%
EPS Revisions
Managers and Directors
Robert M. Davis President, Chief Executive Officer & Director
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Kenneth C. Frazier Executive Chairman
Sandy Tremps Vice President-R&D IT CIO
Dave Williams Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.4.36%202 025
JOHNSON & JOHNSON-3.62%434 036
ROCHE HOLDING AG-4.87%319 830
PFIZER, INC.-10.60%296 303
ABBVIE INC.-2.53%233 325
ELI LILLY AND COMPANY-12.00%220 356